Following the completion of the acquisition on June 3, Noctrix’s flagship product, Nidra will become part of ResMed’s broader sleep medicine portfolio
Highlights strong Vibegron results in older men & real-world prostate cancer insights
Clinical guidelines and expert consensus recommend 1.2–1.5 g/kg/day protein intake during therapy to help preserve muscle mass
Precision medicine company advances Raman spectroscopy-based therapeutic drug monitoring platform for rapid, patient-specific dosing solutions
As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million
The SCOUT-HCM trial hit its primary endpoint, showing a clinically meaningful and statistically significant reduction in Valsalva left ventricular outflow tract
The Cambridge hub is designed to expand Zealand Pharma’s global research capabilities
Germany will be the first launch market
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
